Latest & greatest articles for opioid

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on opioid or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on opioid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for opioid

1. Opioid Treatments for Chronic Pain

Opioid Treatments for Chronic Pain Opioid Treatments for Chronic Pain Comparative Effectiveness Review Number 229 R Comparative Effectiveness Review Number 229 Opioid Treatments for Chronic Pain Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2015-00009-I Prepared by: Pacific Northwest Evidence-based Practice Center Portland, OR Investigators: Roger Chou, M.D. Daniel Hartung (...) , Pharm.D. Judith Turner, Ph.D. Ian Blazina, M.P.H. Brian Chan, M.D. Ximena Levander, M.D. Marian McDonagh, Pharm.D. Shelley Selph, M.D., M.P.H. Rongwei Fu, Ph.D. Miranda Pappas, M.A. AHRQ Publication No. 20-EHC011 April 2020 ii Key Messages Purpose of Review To assess the effectiveness and harms of opioid therapy for chronic noncancer pain, alternative opioid dosing strategies, and risk mitigation strategies Key Messages • Opioids are associated with small improvements versus placebo in pain

2020 Effective Health Care Program (AHRQ)

2. Safety And Efficacy Of The Unique Opioid Buprenorphine For The Treatment Of Chronic Pain Full Text available with Trip Pro

Safety And Efficacy Of The Unique Opioid Buprenorphine For The Treatment Of Chronic Pain Safety And Efficacy Of The Unique Opioid Buprenorphine For The Treatment Of Chronic Pain - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine National Center for Biotechnology Information (...) :3299-3317. doi: 10.2147/JPR.S231948. eCollection 2019. Safety And Efficacy Of The Unique Opioid Buprenorphine For The Treatment Of Chronic Pain , Affiliations Expand Affiliations 1 NEMA Research, Inc., Naples, FL, USA. 2 Neumentum, Palo Alto, CA, USA. 3 University of Arizona College of Pharmacy, Tucson, AZ, USA. 4 Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, PA, USA. PMID: 31997882 PMCID: DOI: Item in Clipboard Review Safety And Efficacy Of The Unique

2020 EvidenceUpdates

3. Naloxone nasal spray (Nyxoid) for opioid overdose

Naloxone nasal spray (Nyxoid) for opioid overdose Naloxone nasal spray (Nyxoid) for opioid overdose - NPS MedicineWise Log In Menu During the COVID-19 pandemic, you need to continue to take your usual medicines and stay as healthy as possible. Here is some important information for everyone to keep in mind. Featured topics 30 Mar 2020 30 Mar 2020 30 Mar 2020 Featured article Information for consumers about medicines and COVID-19 | Updated regularly as the situation changes. Keep a medicines (...) February 2020 19 February 2020 8 January 2020 Featured topic 20 years of helping Australians make better decisions about medicines, medical tests and other health technologies Partner with us Latest projects Search Search Search Search POPULAR Log in Log in All fields are required Email address* Password* Log in Naloxone nasal spray (Nyxoid) for opioid overdose PBS listing of naloxone nasal spray to increase naloxone use as emergency rescue treatment in the community 15 January 2020 Key points Naloxone

2020 National Prescribing Service Limited (Australia)

4. Opioids, chronic pain and the bigger picture

Opioids, chronic pain and the bigger picture OPIOID TAPERING ALGORITHM 1–9 Patient who is taking opioids No meaningful improvement in pain and/or function Cause of pain has resolved Adverse effects are intolerable Risk of harm outweighs potential benefits Signs of aberrant behaviour • Discuss the decision to taper an opioid with the patient • Ask each patient about their treatment goals and their perceived benefits and harms of opioid treatment • Listen to the patient’s beliefs and concerns (...) about, and motivations for, tapering • Discuss the benefits of tapering • Ensure the patient knows that tapering may take several months • Reassure the patient and discuss how you can monitor and support them Does the patient agree to tapering? NO • Revisit the patient’s beliefs and concerns about tapering opioids • Reinforce the rationale for tapering including potential benefits of tapering and harm of continuing long term • Assess for substance use disorder • Discuss the decision to taper

2020 National Prescribing Service Limited (Australia)

5. Prescriber Education Interventions to Optimize Opioid Prescribing in Acute Care: A Systematic Review

Prescriber Education Interventions to Optimize Opioid Prescribing in Acute Care: A Systematic Review Prescriber Education Interventions to Optimize Opioid Prescribing in Acute Care: A Systematic Review - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health (...) Share Permalink Copy Page navigation Pain Physician Actions . 2019 Nov;22(6):E551-E562. Prescriber Education Interventions to Optimize Opioid Prescribing in Acute Care: A Systematic Review , , , , Affiliations Expand Affiliations 1 Pharmacy Department Alfred Health, School of Public Health and Preventative Medicine Monash University, Alfred Hospital, Melbourne, Australia. 2 Pharmacy Department Alfred Health, Anaesthesia and Perioperative Medicine Department Alfred Health, Alfred Hospital, Melbourne

2020 EvidenceUpdates

6. Naldemedine (Rizmoic) - For the treatment of opioid-induced constipation (OIC)

Naldemedine (Rizmoic) - For the treatment of opioid-induced constipation (OIC) Published 13 April 2020 1 SMC2242 naldemedine 200 micrograms film-coated tablets (Rizmoic®) Shionogi BV 06 March 2020 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission naldemedine (Rizmoic ® ) is accepted (...) for use within NHSScotland. Indication under review: For the treatment of opioid induced constipation (OIC) in adult patients who have previously been treated with a laxative. Naldemedine compared to placebo significantly improved the spontaneous bowel movement response rate in patients with opioid induced constipation and either non-cancer or cancer pain. Chairman Scottish Medicines Consortium www.scottishmedicines.org.uk 2 Indication For the treatment of opioid induced constipation (OIC) in adult

2020 Scottish Medicines Consortium

7. Canadian guidelines on opioid use disorder among older adults

Canadian guidelines on opioid use disorder among older adults 123 CANADIAN GERIATRICS JOURNAL, VOLUME 23, ISSUE 1, MARCH 2020 ABSTRACT Background In Canada, rates of hospital admission from opioid overdose are higher for older adults (= 65) than younger adults, and opioid use disorder (OUD) is a growing concern. In response, Health Canada commissioned the Canadian Coalition of Se- niors’ Mental Health to create guidelines for the prevention, screening, assessment, and treatment of OUD in older (...) adults. Methods A systematic review of English language literature from 2008–2018 regarding OUD in adults was conducted. Previ- ously published guidelines were evaluated using AGREE II, and key guidelines updated using ADAPTE method, by drawing on current literature. Recommendations were created and assessed using the GRADE method. Results Thirty-two recommendations were created. Prevention recom- mendations: it is key to prioritize non-pharmacological and non-opioid strategies to treat acute

2020 CPG Infobase

8. Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression

Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Stay at home Only go outside for food, health reasons (...) or work (but only if you cannot work from home) If you go out, stay 2 metres (6ft) away from other people at all times Wash your hands as soon as you get home Do not meet others, even friends or family. You can spread the virus even if you don’t have symptoms. Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression Benzodiazepines and opioids can both cause respiratory depression, which can be fatal if not recognised in time. Only prescribe together

2020 MHRA Drug Safety Update

9. Impact of Timing of Preprocedural Opioids on Adverse Events in Procedural Sedation (Abstract)

Impact of Timing of Preprocedural Opioids on Adverse Events in Procedural Sedation The risk of respiratory depression is increased when opioids are added to sedative agents. In our recent multicenter emergency department (ED) procedural sedation cohort, we reported a strong association between preprocedural opioids and sedation-related adverse events. We sought to examine the association between timing of opioids and the incidence of adverse sedation outcomes.We conducted a secondary analysis (...) of a prospective cohort of children aged 0 to 18 years who received sedation for a painful procedure in six Canadian pediatric EDs from July 2010 to February 2015. The primary risk factor was timing of opioid administration, adjusted for age, opioid type, preprocedural and sedation medications, and procedure type. Outcomes were 1) oxygen desaturation, 2) vomiting, and 3) positive pressure ventilation (PPV).Of the 6,295 children in the original cohort, 1,806 (29%) received a preprocedural opioid. Patients

2020 EvidenceUpdates

10. Fascia Iliaca Block Decreases Hip Fracture Postoperative Opioid Consumption: A Prospective Randomized Controlled Trial (Abstract)

Fascia Iliaca Block Decreases Hip Fracture Postoperative Opioid Consumption: A Prospective Randomized Controlled Trial To determine the efficacy of a preoperative fascia iliaca compartment block in decreasing postoperative pain and improving functional recovery after hip fracture surgery.Randomized prospective Level 1 therapeutic.Academic Level 1 trauma center.Geriatric patients with fractures of the proximal femur (neck, intertrochanteric, or subtrochanteric regions) were prospectively (...) postoperative opioid consumption while improving patient satisfaction. We recommend the integration of this safe and efficacious modality into institutional geriatric hip fracture protocols as an adjunctive pain control strategy.Therapeutic Level II See Instructions for Authors for a complete description of levels of evidence.

2020 EvidenceUpdates

11. Does Integrative Medicine Reduce Prescribed Opioid Use for Chronic Pain? A Systematic Literature Review

Does Integrative Medicine Reduce Prescribed Opioid Use for Chronic Pain? A Systematic Literature Review Does Integrative Medicine Reduce Prescribed Opioid Use for Chronic Pain? A Systematic Literature Review - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes (...) to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Pain Med Actions 2019 Nov 22 [Online ahead of print] Does Integrative Medicine Reduce Prescribed Opioid Use for Chronic Pain? A Systematic Literature Review , , , , , Affiliations Expand Affiliations 1 Canadian College of Naturopathic Medicine, North York, Ontario, Canada. 2 Institute of Medical Science, University of Toronto, Toronto

2020 EvidenceUpdates

12. Benefits and Harms of Long-term Opioid Dose Reduction or Discontinuation in Patients with Chronic Pain

Benefits and Harms of Long-term Opioid Dose Reduction or Discontinuation in Patients with Chronic Pain Management Briefs eBrief-no166 -- Benefits and Harms of Long-term Opioid Dose Reduction or Discontinuation in Patients with Chronic Pain Talk to the Veterans Crisis Line now An official website of the United States government Here's how you know The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're (...) eBrief-no166 -- Benefits and Harms of Long-term Opioid Dose Reduction or Discontinuation in Patients with Chronic Pain Health Services Research & Development Management eBrief no. 166 » Issue 166 January 2020 The report is a product of the VA/HSR&D Evidence Synthesis Program. Benefits and Harms of Long-term Opioid Dose Reduction or Discontinuation in Patients with Chronic Pain In response to the evolving public health crisis related to opioid use, many providers, health systems, and payers

2020 Veterans Affairs - R&D

13. Effect of Intranasal vs Intramuscular Naloxone on Opioid Overdose: A Randomized Clinical Trial Full Text available with Trip Pro

is effective in treating opiate-induced respiratory depression, but is not as effective as IM naloxone. IN delivery of naxolone could reduce the risk of needl … R Chou et al. Ann Intern Med 167 (12), 867-875. 2017. PMID 29181532. - Review Higher-concentration intranasal naloxone (2 mg/mL) seems to have efficacy similar to that of intramuscular naloxone for reversal of opioid overdose, with no difference in … AK Skulberg et al. Addiction 114 (5), 859-867. May 2019. PMID 30644628. Intranasal 1.4 mg naloxone (...) Effect of Intranasal vs Intramuscular Naloxone on Opioid Overdose: A Randomized Clinical Trial Effect of Intranasal vs Intramuscular Naloxone on Opioid Overdose: A Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health U.S

2020 EvidenceUpdates

14. Multimodal opioid-sparing postoperative pain regimen compared with the standard postoperative pain regimen in vaginal pelvic reconstructive surgery: a multicenter randomized controlled trial

Multimodal opioid-sparing postoperative pain regimen compared with the standard postoperative pain regimen in vaginal pelvic reconstructive surgery: a multicenter randomized controlled trial Multimodal Opioid-Sparing Postoperative Pain Regimen Compared With the Standard Postoperative Pain Regimen in Vaginal Pelvic Reconstructive Surgery: A Multicenter Randomized Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set (...) to Collections Create a new collection Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Am J Obstet Gynecol Actions , 221 (5), 511.e1-511.e10 Nov 2019 Multimodal Opioid-Sparing Postoperative Pain Regimen Compared With the Standard Postoperative

2020 EvidenceUpdates

16. Canadian guidelines on opioid use disorder among older adults

pain rises (Johannes et al ., 2010; Schofield, 2018) .10 Canadian Guidelines on Opioid Use Disorder Among Older Adults There are four alkaloid opioids (also called opiates) derived from opium that can be extracted from the poppy plant (Papaver somniferum): morphine, codeine, thebaine, and papaverine . Semi-synthetic opioids include hydromorphone and diacetylmorphine (heroin) . Synthetic mu opioid receptor agonists available by prescription in Canada for the management of pain include tramadol (...) Canadian guidelines on opioid use disorder among older adults Canadian Guidelines on Opioid Use Disorder Among Older Adults 2019 ccsmh.ca2 This publication is intended for information purposes only, and is not intended to be interpreted or used as a standard of medical practice. Best efforts were used to ensure that the information in this publication is accurate; however, the publisher and every person involved in the creation of this publication disclaim any warranty as to the accuracy

2019 CPG Infobase

17. Associations Between Opioid Prescribing Patterns and Overdose Among Privately Insured Adolescents (Abstract)

Associations Between Opioid Prescribing Patterns and Overdose Among Privately Insured Adolescents Little is known about the risk for overdose after opioid prescription. We assessed associations between the type of opioid, quantity dispensed, daily dose, and risk for overdose among adolescents who were previously opioid naive.Retrospective analysis of 1 146 412 privately insured adolescents ages 11 to 17 years in the United States captured in the Truven MarketScan commercial claims data set from (...) January 2007 to September 2015. Opioid overdose was defined as any emergency department visit, inpatient hospitalization, or outpatient health care visit during which opioid overdose was diagnosed.Among our cohort, 725 participants (0.06%) experienced an opioid overdose, and the overall rate of overdose events was 28 events per 100 000 observed patient-years. Receiving ≥30 opioid tablets was associated with a 35% increased risk for overdose compared to receiving ≤18 tablets (hazard ratio [HR] = 1.35

2019 EvidenceUpdates

18. Managing Acute Pain in Patients Taking Medications for Opioid Use Disorder

Managing Acute Pain in Patients Taking Medications for Opioid Use Disorder Management Briefs eBrief-no160 -- Managing Acute Pain in Patients Taking Medications for Opioid Use Disorder Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs eBrief-no160 -- Managing Acute Pain in Patients Taking Medications for Opioid Use Disorder Health Services Research & Development Management eBrief (...) no. 160 » Issue 160 October 2019 The report is a product of the VA/HSR&D Evidence Synthesis Program. Evidence Brief: Managing Acute Pain in Patients Taking Medications for Opioid Use Disorder Acute pain management in patients with opioid use disorder (OUD) can be challenging due to several factors including increased pain sensitivity and higher opioid tolerance. Use of medications for OUD (MOUD) including methadone, buprenorphine/naloxone, or naltrexone adds to the complexity of acute pain management

2019 Veterans Affairs - R&D

19. Barriers and Facilitators to Use of Medications for Opioid Use Disorder

Barriers and Facilitators to Use of Medications for Opioid Use Disorder Management Briefs eBrief-no159 -- Barriers and Facilitators to Use of Medications for Opioid Use Disorder Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs eBrief-no159 -- Barriers and Facilitators to Use of Medications for Opioid Use Disorder Health Services Research & Development Management eBrief no. 159 » Issue (...) 159 October 2019 The report is a product of the VA/HSR&D Evidence Synthesis Program. Evidence Brief: Barriers and Facilitators to Use of Medications for Opioid Use Disorder As a component of VA’s overall response to the crisis of opioid-related morbidity and mortality, VA provides treatment for those with opioid use disorder (OUD; i.e. ICD-10 opioid dependence), a diagnosis made based on symptoms (i.e., drug cravings) and behaviors (i.e., inability to cut down or control substance use despite

2019 Veterans Affairs - R&D

20. Buprenorphine for Opioid Use Disorder: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines

Buprenorphine for Opioid Use Disorder: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines Buprenorphine for Opioid Use Disorder: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Buprenorphine for Opioid Use Disorder: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines Buprenorphine for Opioid Use Disorder: A Review of Comparative (...) Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines Last updated: April 24, 2019 Project Number: RC1092-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of various buprenorphine or buprenorphine-naloxone (BUP-NAL) formulations versus other buprenorphine formulations for the treatment of opioid use disorder (OUD)? What is the clinical evidence regarding the safety of various

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review